Psychedelic Therapeutics for Adolescents: Ethics, Safety, Opportunities, and Equipoise.
Journal of the American Academy of Child and Adolescent Psychiatry December 19, 2024 Paul E Croarkin, Isabella Sutherland, Ming-Fen Ho 1 citation
A commentary responds to an earlier article advocating for clinical trials of psychedelic-assisted therapy in adolescents aged 16 to 17. The authors agree that rigorous studies of compounds like psilocybin, LSD, and MDMA in this age group are warranted, as adolescents are likely already using these substances therapeutically. They offer additional considerations to foster further dialogue and advocacy in the field.